Correction: Humoral response to a viral glycan correlates with survival on PROSTVAC-VF (Proceedings of the National Academy of Sciences of the United States of America (2014) 111, 17, (E1749-E1758) DOI: 10.1073/pnas.1314722111);Humoral response to a viral glycan correlates with survival on PROSTVAC-VF

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 17, 2014, Pages E3451-

  Campbell, Christopher T ^a   Gulley, James L ^b   Oyelaran, Oyindasola ^a,c   Hodge, James W ^b   Schlom, Jeffrey ^b   Gildersleeve, Jeffrey C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Forssman antigen; Glycan array

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE; DISACCHARIDE; DOCETAXEL; GLYCAN; LEXIDRONAM SAMARIUM SM 153; ORTHOPOXVIRUS VACCINE; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

FORSSMAN ANTIGEN; GLYCAN ARRAY;

ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; CANCER VACCINES; DISACCHARIDES; FOWLPOX VIRUS; GENETIC VECTORS; GLYCOMICS; HUMANS; IMMUNITY, HUMORAL; KAPLAN-MEIER ESTIMATE; MALE; POLYSACCHARIDES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VACCINATION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84899630848     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510832112     Document Type: Erratum

References (66)

1. Kantoff PW, et al.; IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422.
2. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265-277.
3. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480-489.
4. Wolchok JD, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15(23):7412-7420.
5. Cipriani B (2009) Immunological markers of cancer vaccine efficacy and their clinical relevance. Biomarkers Med 3(3):253-264.
6. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60(3):433-442.
7. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357(21):2189-2194.
8. Andre F, et al. (2011) Biomarker studies: A call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8(3):171-176.
9. Ransohoff DF, Gourlay ML (2010) Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 28(4):698-704.
10. Walter S, et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8): 1254-1261.
11. Sheikh NA, et al. (2013) Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62(1):137-147.
12. Hakomori S (2002) Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA 99(16):10231-10233.
13. Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4(6):477-488.
14. Gilewski TA, et al. (2007) Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 13(10):2977-2985.
15. Ragupathi G, et al. (2009) Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother 58(9):1397-1405.
16. Astronomo RD, Burton DR (2010) Carbohydrate vaccines: Developing sweet solutions to sticky situations? Nat Rev Drug Discov 9(4):308-324.
17. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF (1999) IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112(2):205-209.
18. Ravindranath MH, et al. (1998) Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 75(1):117-124.
19. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM (1996) Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 42(5):303-309.
20. Rillahan CD, Paulson JC (2011) Glycan microarrays for decoding the glycome. Annu Rev Biochem 80:797-823.
21. Oyelaran O, Gildersleeve JC (2009) Glycan arrays: Recent advances and future challenges. Curr Opin Chem Biol 13(4):406-413.
22. BN ImmunoTherapeutics (2014) A randomized, double-blind, phase 3 efficacy trial of PROSTVAC +/-GM-CSF inmenwith asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (Prospect). Available at: http://clinicaltrials.gov/ct/show/NCT01322490. Accessed April 3, 2014.
23. Gulley JL, et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59(5):663-674.
24. Kantoff PW, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 28(7):1099-1105.
25. Ranieri E, et al. (2000) Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunol Invest 29(2):121-125.
26. Campbell CT, et al. (2013) Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res 19(5):1290-1299.
27. Oyelaran O, McShane LM, Dodd L, Gildersleeve JC (2009) Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res 8(9):4301-4310.
28. Ménard C, et al. (2006) Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66(3):1844-1850.
29. Gulley JL, Madan RA, Arlen PM (2007) Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25(Suppl 2):B89-B96.
30. National Cancer Institute (2013) 153Sm-EDTMP with or without a PSA/TRICOM vaccine to treat men with androgen-insensitive prostate cancer. National Library of Medicine NLM Identifier:NCT00450619. Available at: http://clinicaltrials.gov/ct/show/NCT00450619. Accessed April 3, 2014.
31. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A (1992) Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 33(8):1451-1458.
32. Xu H, Storch T, Yu M, Elliott SP, Haslam DB (1999) Characterization of the human Forssman synthetase gene. An evolving association between glycolipid synthesis and host-microbial interactions. J Biol Chem 274(41):29390-29398.
33. Svensson L, et al. (2013) Forssman expression on human erythrocytes: Biochemical and genetic evidence of a new histo-blood group system. Blood 121(8):1459-1468.
34. Briles WE (1984) Early chicken blood group investigations. Immunogenetics 20(3): 217-226.
35. Szepsenwol J, Witersky E (1934) Research on the "Forssman" antigen in eggs and in various parts of chicken embryos. C R Seances Soc Biol Fil 115:1019-1020.
36. Leduc EH, Tanaka N (1956) A study of the cellular distribution of Forssman antigen in various species. J Immunol 77(3):198-212.
37. Krishnamoorthy L, Bess JW, Jr., Preston AB, Nagashima K, Mahal LK (2009) HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol 5(4):244-250.
38. Springer GF, Schuster R (1964) [Blood group A-like Forssman antigens in myxoviruses cultured in a chicken egg: Their possible pathogenetic significance in vaccines]. Klin Wochenschr 42:821-823. German.
39. Springer GF, Tritel H (1962) Blood group A active substances in embryonated chicken eggs and their relation to egggrown virus. Science 138(3541):687-688.
40. Rott R, Drzenick R, Saber MS, Reichert E (1966) Blood group substances forssman and mononucleosis antigens in lipid-containing RNA viruses. Arch Gesamte Virusforsch 19(3):273-288.
41. Gulley JL, et al. (2014) Immune Impact Induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immun. Res. 2:133-141.
42. Rossi GR, et al. (2005) Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res 65(22):10555-10561.
43. Mandell RB, et al. (2009) The αGal HyperAcute(-) technology: Enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade. Zoonoses Public Health 56(6-7):391-406.
44. Deguchi T, et al. (2010) Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: A novel approach to immunotherapy in pancreatic cancer. Cancer Res 70(13):5259-5269.
45. Dürrbach A, Baple E, Preece AF, Charpentier B, Gustafsson K (2007) Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation. Eur J Immunol 37(5):1254-1265.
46. Berlyn KA, et al. (2001) Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 101(3):276-283.
47. NewLink Genetics Corporation (2013) Immunotherapy study for surgically resected pancreatic cancer. National Library of Medicine Identifier: NCT0107298. Available at: www.clinicaltrials.gov/ct2/show/NCT01072981. Accessed April 3, 2014.
48. Gulley JL, Drake CG (2011) Immunotherapy for prostate cancer: Recent advances, lessons learned, and areas for further research. Clin Cancer Res 17(12):3884-3891.
49. Petrylak DP, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520.
50. Tannock IF, et al.; TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
51. de Bono JS, et al.; TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376(9747):1147-1154.
52. Scher HI, et al.; AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187-1197.
53. de Bono JS, et al.; COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005.
54. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
55. Madan RA, et al. (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol 13(5):501-508.
56. Gulley JL, et al. (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14(10): 3060-3069.
57. Jäger E, et al. (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103(39):14453-14458.
58. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
59. Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: A novel multimechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64-71.
60. Breitbach CJ, et al. (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362):99-102.
61. Manimala JC, Roach TA, Li Z, Gildersleeve JC (2007) High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 17(8):17C-23C.
62. Manimala JC, Roach TA, Li Z, Gildersleeve JC (2006) High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl 45(22):3607-3610.
63. Campbell CT, Zhang Y, Gildersleeve JC (2010) Construction and use of glycan microarrays. Curr Protoc Chem Biol 2(1):37-53.
64. Manimala JC, Li Z, Jain A, VedBrat S, Gildersleeve JC (2005) Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development. ChemBioChem 6(12):2229-2241.
65. Allison DB, Cui X, Page GP, SabripourM(2006) Microarray data analysis: From disarray to consolidation and consensus. Nat Rev Genet 7(1):55-65.
66. Lin JT (1988) Alternatives to hamakers approximations to the cumulative normaldistribution and its inverse. Statistician 37(4-5):413-414.